| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/20/2002 | WO2002047708A2 Selective cox-2 inhibition from edible plant extracts |
| 06/20/2002 | WO2002047707A2 Selective cox-2 inhibition from non-edible plant extracts |
| 06/20/2002 | WO2002047706A2 Selective cox-2 inhibition from plant extracts |
| 06/20/2002 | WO2002047705A2 Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use |
| 06/20/2002 | WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 06/20/2002 | WO2002047697A2 Fractions of snake blood, their preparation and use as therapeutic agents |
| 06/20/2002 | WO2002047673A2 Methods and compositions to treat conditions associated with neovascularization |
| 06/20/2002 | WO2002047611A2 Cddo-compounds and combination therapies thereof |
| 06/20/2002 | WO2002047604A2 Novel use of chalcone class compounds for inhibiting tumoral mass vascularization |
| 06/20/2002 | WO2002047534A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 06/20/2002 | WO2002047474A1 Transgenic animal expressing hla-a24 and utilization thereof |
| 06/20/2002 | WO2002040518A8 Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant |
| 06/20/2002 | WO2002030894A3 Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins |
| 06/20/2002 | WO2002030888A3 Tricyclic compounds and uses thereof |
| 06/20/2002 | WO2002028905A3 Human anti-cd40 antibodies |
| 06/20/2002 | WO2002026759A3 17α FLUOROALKYL STEROIDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS |
| 06/20/2002 | WO2002024681A3 Pyrazine derivatives as modulators of tyrosine kinases |
| 06/20/2002 | WO2002020495A3 Inhibitors of glycogen synthase kinase 3 |
| 06/20/2002 | WO2002016312A3 NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY |
| 06/20/2002 | WO2002008291A3 Multi-specific reagent for selective stimulation of cell surface receptors |
| 06/20/2002 | WO2002007740A3 Snake toxin and use thereof as a pharmaceutical |
| 06/20/2002 | WO2002003910A3 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation |
| 06/20/2002 | WO2002000711A3 Ev-vegf nucleic acids and polypeptides and methods of use |
| 06/20/2002 | WO2001092876A3 Method for identifying compounds for modulating the activity of a tumour suppressor protein |
| 06/20/2002 | WO2001090152A3 Compositions and methods for the therapy and diagnosis of breast cancer |
| 06/20/2002 | WO2001087977A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| 06/20/2002 | WO2001085959A3 Regulation of human lysostaphin-like protease |
| 06/20/2002 | WO2001085942A3 Cytoskeleton-associated proteins |
| 06/20/2002 | WO2001085941A3 Myc targets |
| 06/20/2002 | WO2001083524A3 Rna metabolism proteins |
| 06/20/2002 | WO2001083436A3 Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
| 06/20/2002 | WO2001081417A3 Use of taci as an anti-tumor agent |
| 06/20/2002 | WO2001078705A3 Compositions containing a naphthalmide and an antiproliferative agent |
| 06/20/2002 | WO2001077164A3 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 06/20/2002 | WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 06/20/2002 | WO2001068851A3 Polypeptides and nucleic acids encoding same |
| 06/20/2002 | WO2001068068A3 Compounds capable of binding with the cytoskeleton |
| 06/20/2002 | WO2001068066A3 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 06/20/2002 | WO2001062298A3 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 06/20/2002 | WO2001056590A3 Utilization of protein kinase inhibitor alpha |
| 06/20/2002 | WO2001054771A3 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/20/2002 | WO2001052837A3 Use of at least a fatty ester for preparing a composition designed to inhibit 5-$g(a)-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive |
| 06/20/2002 | WO2001051633A3 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 06/20/2002 | WO2001047505A3 Use of azoles for preventing skin cancer |
| 06/20/2002 | WO2001044445A8 Human lyases and associated proteins |
| 06/20/2002 | WO2001032693A3 Trp-protein-related mtr1 protein and dna sequence coding therefor |
| 06/20/2002 | WO2001030328A3 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 06/20/2002 | WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 06/20/2002 | WO2000075333A9 Streptavidin expressed gene fusions and methods of use thereof |
| 06/20/2002 | WO2000067734A3 Use of phthalazine derivatives |
| 06/20/2002 | WO2000061750A9 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 06/20/2002 | WO2000061596A8 50 human secreted proteins |
| 06/20/2002 | WO2000052210A9 Methods for targeting rna molecules |
| 06/20/2002 | WO2000052158A9 Methods and reagents for inhibiting angiogenesis |
| 06/20/2002 | US20020077520 Device and method for dilating and irradiating a vascular segment or body passageway |
| 06/20/2002 | US20020077476 Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia |
| 06/20/2002 | US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis |
| 06/20/2002 | US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition |
| 06/20/2002 | US20020077356 Nonsteroidal antiinflammatory agents |
| 06/20/2002 | US20020077351 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation |
| 06/20/2002 | US20020077341 C10 carbamoyloxy substituted taxanes |
| 06/20/2002 | US20020077339 Chemokine receptor binding heterocyclic compounds |
| 06/20/2002 | US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2) |
| 06/20/2002 | US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis |
| 06/20/2002 | US20020077325 New camptothecin analogue compounds |
| 06/20/2002 | US20020077321 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 06/20/2002 | US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder |
| 06/20/2002 | US20020077313 Methods and compositions for the diagnosis and treatment of cancer |
| 06/20/2002 | US20020077301 Administering combination of farnesyl transferase inhibitor (FTI) and signal transduction inhibitor (STD in a therapeutically effective amount, wherein proliferation of cells is reduced and/ or apoptosis of cells is enhanced |
| 06/20/2002 | US20020077289 Angiostatin and endostatin binding proteins and methods of use |
| 06/20/2002 | US20020077283 Blocking interaction of caveolin with a protein in vivo by administering peptide which comprises caveolin scaffolding domain |
| 06/20/2002 | US20020077279 Manufacture of polyglutamate-therapeutic agent conjugates |
| 06/20/2002 | US20020076800 Protein |
| 06/20/2002 | US20020076796 2786, a novel human aminopeptidase |
| 06/20/2002 | US20020076795 Novel TRF1 binding protein, methods of use thereof |
| 06/20/2002 | US20020076783 Plants and plants cells expressing histidine tagged intimin |
| 06/20/2002 | US20020076736 Methods of affecting laminin 5 processing |
| 06/20/2002 | US20020076710 Detection and treatment of breast disease |
| 06/20/2002 | US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain |
| 06/20/2002 | US20020076457 Extracts of plants of genus Euphorbia, in particular sap of Euphorbia peplus, Euphorbia hirta and/or Euphorbia drummondii; selective cytotoxicity against malignant melanomas and squamous cell carcinomas |
| 06/20/2002 | US20020076446 Novel medicinal herbal composition for treating liver diseases and HIV |
| 06/20/2002 | US20020076441 A biodegradable gel matrix and a microparticle system wherein the microparticle is embedded in the biodegradable gel matrix, from which bioactive agent is released in a controlled manner |
| 06/20/2002 | US20020076416 Chimeric peptide immunogens |
| 06/20/2002 | US20020076413 Administering fragments, conformations, biological equivalent, or derivatives of antithrombin III; anticancer agents |
| 06/20/2002 | US20020076409 Method for treating cancer |
| 06/20/2002 | US20020076406 Multivalent target binding protein |
| 06/20/2002 | US20020076395 Modified adipose tissue and related implants and methods |
| 06/20/2002 | US20020076392 Non-antibody immunomodulatory molecules such as cytokines expressed as membrane-bound fusion proteins; vaccines; immunotherapy |
| 06/20/2002 | US20020076377 Novel bifunctional chelating compounds containing hydroxamic acid residues |
| 06/20/2002 | DE10063173A1 Harnstoff- und Urethanderivate Urea and urethane |
| 06/20/2002 | DE10063008A1 Carbonsäureamidderivate Carboxamide |
| 06/20/2002 | DE10061161A1 Neue humane Androgenrezeptor-Varianten New human androgen receptor variants |
| 06/20/2002 | DE10060809A1 Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker Substituted anthranilic acids, their use as a medicament or diagnostic, and she containing drug, as well as a pharmaceutical combination preparation with a sodium / hydrogen exchange (NHE) blockers |
| 06/20/2002 | DE10060677A1 Klainetine und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben Klainetins and their derivatives, process for their preparation and use thereof |
| 06/20/2002 | DE10060292A1 Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibiting the Na + / H + exchanger and containing medicament |
| 06/20/2002 | CA2434915A1 Therapeutic agent comprising a b-subunit of a protein toxin |
| 06/20/2002 | CA2431858A1 Targeted enzymes comprising substrate recognition sites and target binding sites |
| 06/20/2002 | CA2431766A1 Carboxymide derivatives and their use in the treatment of thromboembolic diseases and tumours |
| 06/20/2002 | CA2431716A1 Targeted enzyme prodrug therapy |
| 06/20/2002 | CA2431406A1 Quinazolinone derivatives |